Group One Trading
PRLD icon

Group One Trading’s Prelude Therapeutics PRLD Stock Holding History

Group One Trading’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Hold
3,900
– – ﹤0.01% 5990
2026
Q1 		$13.3K Buy
+3,900
New +$10.2K ﹤0.01% 6201

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Group One Trading's PRLD Position: Q2 2026 in Review

Group One Trading held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 3,907 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5986.

Group One Trading first reported a position in PRLD in Q3 2024 and has held it in 8 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Group One Trading held 3,907 shares of Prelude Therapeutics worth $20.8K as of Q2 2026.
  • Group One Trading left its Prelude Therapeutics share count unchanged in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5986 holding.
  • Group One Trading first reported a position in Prelude Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.